Sjögren’s Disease Leads To Mental Health Meltdown
Overview
Primary Sjögren’s syndrome (pSS) is a well-known autoimmune disorder characterized by inflammation of the glands, leading to symptoms such as dry eyes and mouth. While traditionally associated with peripheral glandular issues, Sjögren’s syndrome also impacts the central nervous system (CNS), manifesting in various neuropsychiatric symptoms. Despite its significance, research on the psychiatric comorbidities linked to Sjögren’s syndrome remains limited.
This narrative review was based on an extensive search of PubMed and Google Scholar, covering literature up to August 2023, to examine psychiatric manifestations in pSS and explore potential underlying mechanisms. The findings revealed that depression and cognitive dysfunction are the most prevalent psychiatric complications in pSS patients. Additionally, other psychiatric symptoms, including anxiety, sleep disturbances, psychosis, catatonia, bipolar disorder, and obsessive-compulsive disorder, have been documented in these individuals.
In summary, individuals with Sjögren’s syndrome frequently experience a range of psychiatric symptoms that can substantially disrupt daily functioning and diminish quality of life. Therefore, timely diagnosis and appropriate management of these psychiatric manifestations are essential.
Introduction
Sjögren’s syndrome (SS) is an autoimmune disease characterized by the infiltration of mononuclear cells, leading to damage in the salivary and lacrimal glands. SS can present as secondary Sjögren’s syndrome, associated with another autoimmune condition, or as primary Sjögren’s syndrome (pSS) when it occurs independently. The prevalence of Sjögren’s syndrome varies globally, affecting about 0.1% to 3% of the general population, with a strong female predominance at a ratio of approximately 9:1. Recent studies indicate that pSS may also impact the nervous system, resulting in various psychiatric symptoms. However, there is limited research on the epidemiology of these psychiatric comorbidities in individuals with Sjögren’s syndrome. The reported prevalence of psychiatric manifestations in pSS varies significantly across studies due to methodological differences. It appears that psychiatric disorders are often primary manifestations of Sjögren’s syndrome rather than secondary to disease complications, treatment, or unrelated events.
Psychiatric conditions associated with Sjögren’s syndrome include cognitive dysfunction, commonly referred to as “brain fog,” as well as depression, bipolar disorder, psychosis, catatonia, and obsessive-compulsive disorder. Cognitive dysfunction, affecting attention, memory, and information processing, is the most frequently reported psychiatric symptom in pSS patients, often followed by depression, which severely impacts the quality of life.
The exact mechanisms underlying psychiatric involvement in Sjögren’s syndrome remain unclear, but several hypotheses have been proposed. Potential mechanisms include the presence of anti-neuronal antibodies (such as anti-NR2 antibodies, anti-P antibodies, and anti-AQP4 antibodies), inflammation-related disturbances in the central nervous system (CNS), neurotransmitter dysregulation, and ischemic damage caused by CNS vasculitis. Diagnosing these psychiatric manifestations is challenging due to the lack of specific biomarkers and the overlap of symptoms with other rheumatic and psychiatric disorders. Thus, collaboration between rheumatologists, neurologists, and psychiatrists is essential for accurate diagnosis and effective management.
Treatment for these psychiatric manifestations is multidimensional, aiming to alleviate symptoms, enhance quality of life, and address the underlying autoimmune process. Symptomatic treatments may include cognitive rehabilitation, antidepressant and anxiolytic medications, and pain management. Immunomodulatory therapies, such as corticosteroids, disease-modifying antirheumatic drugs, and biologics, should also be considered.
These psychiatric symptoms significantly affect the quality of life and may be the primary presenting features in 50% to 80% of pSS patients, further complicating the diagnosis. Therefore, it is crucial to screen for these complications early in the disease course and to treat them with the most effective options available.
This paper aims to review existing literature to deepen the understanding of psychiatric manifestations in Sjögren’s syndrome, focusing on the underlying mechanisms, clinical presentations, diagnostic challenges, and treatment strategies.
Method
For this narrative review, we performed an extensive search of PubMed and Google Scholar up to August 2023, aiming to identify studies related to psychiatric symptoms in primary Sjögren’s syndrome (pSS) and their potential underlying mechanisms. Our search encompassed all available publication dates, with the review limited to English-language articles. We employed search terms such as “Sjögren’s syndrome,” “Sjögren,” “psychiatric manifestations,” “psychiatric conditions,” “bipolar,” “obsessive-compulsive,” “obsession,” “anxiety disorder,” “depressive disorder,” “sleep disorder,” “catatonia,” “psychosis,” and “cognitive impairment.” After identifying relevant articles, we further examined their reference lists to discover additional sources. Gray literature was excluded from this search process.
Result
A comprehensive review was conducted, involving an initial identification of 1500 records through a database search, followed by title and abstract screening. After a detailed full-text examination, 1395 papers were excluded, leaving 105 articles for inclusion in the study. The study focused on psychiatric complications in primary Sjögren’s syndrome (pSS), with depression and cognitive dysfunction being the most frequently reported issues. Other psychiatric manifestations observed in Sjögren’s syndrome patients included anxiety, sleep disorders, psychosis, catatonia, bipolar disorder, and obsessive-compulsive disorder (OCD).
The study explored these psychiatric manifestations extensively, addressing their potential underlying pathophysiology, as well as their diagnosis and treatment strategies. Sleep disturbances emerged as a significant issue in pSS patients, with 75% reporting moderate to severe sleep disruptions. A recent meta-analysis confirmed that pSS patients experienced more sleep problems, including drowsiness, nocturnal awakenings, and sleep quality issues. These disturbances were linked to mood disorders, pain, and symptoms related to pSS, such as dryness and restless leg syndrome. Effective management of sleep problems in pSS requires a holistic approach, including immunosuppressive medications and cognitive behavioral therapy for insomnia.
Psychosis and catatonia were identified as less common but significant complications of Sjögren’s syndrome. Although depression is a frequent comorbidity, psychosis is rarer, affecting about 8% of pSS patients with central nervous system (CNS) involvement. Catatonia, a condition characterized by motor and behavioral symptoms, has been linked to neuroinflammation and immune system dysregulation in pSS. Case studies highlighted the successful treatment of pSS-related psychosis and catatonia with immunosuppressive therapies, such as rituximab and corticosteroids.
The connection between obsessive-compulsive disorder (OCD) and Sjögren’s syndrome was also explored, with studies indicating an increased risk of OCD in pSS patients. Some case reports revealed that OCD symptoms in pSS patients improved significantly with immunotherapy, suggesting a potential link between the immune response and OCD.
Bipolar disorder (BD) was another psychiatric condition associated with Sjögren’s syndrome, though research on this connection remains limited. Case studies showed that mood stabilizers and immunosuppressive treatments could effectively manage BD in Sjögren’s syndrome patients. However, caution was advised with the use of corticosteroids due to their potential to trigger psychiatric symptoms.
Anxiety and depression were found to be common among Sjögren’s syndrome patients, with prevalence rates as high as 46%. The study discussed several potential mechanisms linking pSS to depression, including psychological distress, physical discomfort from Sjögren’s syndrome symptoms, and immune dysfunction. The treatment of depression in pSS patients may benefit from a combination of antidepressants, psychotherapy, and lifestyle interventions, although care must be taken to avoid exacerbating pSS-related symptoms, such as dry eye disease.
Finally, cognitive dysfunction was identified as a prevalent issue in Sjögren’s syndrome patients, often manifesting as difficulties with memory, concentration, and information processing. The study emphasized the need for MRI scans and other diagnostic tools to assess cognitive impairment in Sjögren’s syndrome patients and explore the potential benefits of immunomodulatory treatments. Overall, the study highlighted the complex interplay between Sjögren’s syndrome and various psychiatric and cognitive disorders, underscoring the importance of comprehensive diagnostic and treatment approaches to improve patient outcomes.
Conclusion
In summary, patients with primary Sjögren’s syndrome (pSS) commonly present with a variety of psychiatric symptoms that include anxiety, sleep disturbances, psychosis, catatonia, bipolar disorder, cognitive dysfunction, and obsessive-compulsive disorder. These manifestations can sometimes be the primary indicators of pSS, rather than the more commonly recognized physical symptoms. When psychiatric issues emerge as the initial symptoms, they can significantly impair daily functioning and lead to a decreased quality of life for patients.
The presence of these psychiatric symptoms in Sjögren’s syndrome can complicate the clinical picture, often resulting in delayed diagnosis and treatment. Since these psychiatric manifestations can substantially affect a patient’s overall well-being and functional capacity, it is crucial to recognize and address them promptly. Early and accurate diagnosis, followed by targeted management strategies, is essential to mitigate the impact of these symptoms and improve both functional outcomes and quality of life for individuals with Sjögren’s syndrome.
Effective management requires a multidisciplinary approach that integrates both rheumatological and psychiatric care. Coordinating care among specialists can help ensure that patients receive comprehensive treatment that addresses both the physical and psychological aspects of their condition. By prioritizing timely intervention and holistic care, healthcare providers can better support patients in managing the complex challenges associated with primary Sjögren’s syndrome.
Oncology Related Tools
Other
Latest Research
